Depo-Provera Shortage: What Providers and Prescribers Need to Know in 2026

For providers who prescribe Depo-Provera (medroxyprogesterone acetate injectable suspension, DMPA-IM), 2026 brings two distinct challenges: ongoing patient questions about access and a major regulatory update that fundamentally changes the risk-benefit discussion for this contraceptive. This article consolidates what you need to know to manage your patients effectively.

Current Availability Status

Depo-Provera is not listed on the FDA Drug Shortage Database as of 2026. The national supply of medroxyprogesterone acetate injectable suspension (150 mg/mL) remains intact, with Pfizer manufacturing both the brand-name product and a generic sold under the Prasco label. Multiple other generic manufacturers are also active in the market.

Despite no formal shortage, providers should be aware that:

Retail pharmacy stocking of injectable medroxyprogesterone is inconsistent, particularly in rural and underserved areas where demand-based ordering leaves many pharmacies without stock.

Many patients receive the injection directly at your practice or through Title X family planning clinics, so maintaining an adequate in-office supply is important.

Prescribing patterns may shift in response to the December 2025 label change (see below), which could affect local pharmacy stock levels over time.

The December 2025 Meningioma Label Update: Clinical Implications

The FDA approved a significant update to the Depo-Provera CI and Depo-SubQ Provera 104 prescribing information in December 2025, adding an explicit meningioma warning. The approved label language states:

"Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed."

This warning follows accumulating epidemiologic evidence:

A 2024 French case-control study (BMJ) found a 5.6-fold increased risk of meningioma requiring surgery in women using DMPA for more than one year.

A September 2025 U.S. population study analyzing more than 10 million women found a 2.5-fold increased meningioma risk among DMPA users.

An August 2025 study found a 3.5-fold elevated risk.

Canada and the EU had required meningioma warnings since 2022–2024; this update brings the U.S. label in line with international standards.

Note that this is not a black box warning—the existing black box warning pertains to bone mineral density loss. The meningioma warning is a cautionary statement within the prescribing information's Warnings and Precautions section.

Counseling Patients on the Meningioma Risk

Key counseling points for patients currently on or considering Depo-Provera:

Absolute risk remains low, but relative risk increases with duration of use—particularly beyond one year.

Patients with a prior history of meningioma should not use Depo-Provera.

Advise patients to report new or worsening headaches, visual disturbances, loss of smell, weakness, or cognitive changes—which may be early meningioma symptoms.

For patients using Depo-Provera beyond the recommended 2-year limit (due to limited alternatives), meningioma risk should be included in shared decision-making.

Managing the Existing Black Box Warning: Bone Mineral Density

The FDA has long maintained a black box warning that Depo-Provera should not be used as a long-term (>2 year) birth control method unless other options are considered inadequate, due to significant bone mineral density (BMD) loss. In adolescents, BMD loss at the total hip and femoral neck did not fully recover by 5 years (60 months) post-treatment in patients using it for more than 2 years. In adults, there was only partial recovery at 2 years post-treatment.

Note: ACOG and WHO disagree with the FDA's 2-year restriction, stating that BMD loss from DMPA is not associated with clinical fractures and appears reversible. Continue to use clinical judgment when counseling patients who rely on Depo-Provera due to limited access to or suitability of alternatives.

Clinical Alternatives to Discuss with Patients

When discussing alternatives for patients concerned about meningioma risk or bone density:

Nexplanon (etonogestrel implant): Long-acting, progestin-only, no bone density warning, no meningioma association, 3-year duration

Levonorgestrel IUDs (Mirena, Kyleena, Liletta): Localized progestin delivery, lower systemic exposure, 3–8 year duration, no meningioma or BMD concerns

Copper IUD (Paragard): Hormone-free, 10–12 years, no systemic hormonal effects—appropriate for patients who want to avoid all hormones

Depo-SubQ Provera 104: Lower dose, self-injectable—note that the meningioma warning applies to this formulation as well

Helping Patients Access Depo-Provera Injections

For patients who are continuing on Depo-Provera and struggling to find it, medfinder for Providers is a tool that checks real-time pharmacy availability near your practice, helping you direct patients to locations that currently have stock. This is particularly useful for patients in rural or underserved areas where supply is inconsistent.

For a detailed practical workflow, see: How to Help Your Patients Find Depo-Provera in Stock: A Provider's Guide.